New Aspects in Sustained Drug Release Formulations

Abstract

Nowadays, pharmaceutical technology and research for new drugs and formulations is of great importance, as scientists attempt to discover even more revolutionary and efficient methods to treat various diseases. At the same time the correct dosing and site targeting are equally important for clinical success. Research in sustained drug release systems is very promising towards such a direction, while it offers advantages and potential rewards contrary to traditional therapy. The drug plasma concentrations remain inside the therapeutic range for a longer time period compared to the conventional formulations. In addition, sustained release formulations may increase the likelihood for the patient to respond to the therapy, since drug formulations are generally characterized by one daily given dose. The rate at which a drug is released from a sustained-release formulation depends upon many factors, while excipients play the most important role. Most sustained release formulations are based on biodegradable polymers in the form of a drug-encapsulating matrix or membrane. Examples range from monolithic devices, polymer-coated capsules and implant devices, hydrogels, to injectable systems based on suspensions of micro-, nanospheres or polymer solutions. The advantages and disadvantages of these different formulation systems are being extensively discussed in the present review.

Benzazaborinines as Novel Bioisosteric Replacements of Naphthalene: Propranolol as an Example

“…One limitation we have observed for 1,2-benzazaborinines is their acid sensitivity, which poses a challenge for the development of oral drugs containing 1,2-benzazaborinines. However, technologies exist like enteric coated capsules or coformulation with proton pump inhibitors, which should allow the development of 1,2-benzazaborinines as oral drugs . Overall our data support the potential of 1,2-benzazaborinines as bioisosteric replacements for naphthalene in drug discovery programs, including those targeting CNS indications.…”

“…However, technologies exist like enteric coated capsules or coformulation with proton pump inhibitors, which should allow the development of 1,2-benzazaborinines as oral drugs. 32 Overall our data support the potential of 1,2-benzazaborinines as bioisosteric replacements for naphthalene in drug discovery programs, including those targeting CNS indications.…”

Second Prize: Sustained Release Varnish Containing Chlorhexidine for Prevention of Biofilm Formation on Urinary Catheter Surface: In Vitro Study

“…The use of sustained release delivery systems such as the SRV allows a graduated release of the drug and therefore better antibacterial efficacy against the bacteria immobilized in the biofilm. 15,22 Many techniques have been suggested to affect the P. aeruginosa biofilm on catheters. [23][24][25][26][27][28] The SRV technology has numerous pharmacologic advantages that stem from the ability to control the release of the drug from the matrix of the SRV, prolong duration of the drug at the desired site, better penetration into the biofilm layers, and reduced systemic and local side effects because the amounts of drug released are low.…”

The potential of functionalized dressing releasing flavonoids facilitates scar-free healing

“…Topical application of pure compounds has a short duration of action, low stability, and can cause undesirable side effects, 10.3389/fmed.2022.978120 whereas sustained release of bioactive drugs can maintain drug levels in vivo for a long time with little changes (129). The drug concentration can be kept within the therapeutic range by encapsulating the drug in carriers such as particles, nanoparticles, and hydrogels to release the drug at a steady rate, extending the duration of action and enhancing the drug's bioavailability (130).…”